SARS-CoV-2 whole genome sequencing in SAB-185 for Non-hospitalized Adults with COVID-19
The ACTIV-2/A5401 platform was designed to evaluate multiple investigational agents for outpatient COVID-19 treatment. For the phase 3 trial of SAB-185, participants were randomized 1:1 to open-label SAB-185 (3,840 units/kg) or casirivimab/imdevimab (600 mg/600 mg) given once by intravenous infusion.